Exploring the clonal evolution and treatment resistance in chronic lymphocytic leukemia
Školitel: RNDr. Jitka Malcikova, Ph.D.
Instituce: Masaryk University, Faculty of Medicine
O mém projektu
Chronic lymphocytic leukemia is the most common leukemia in the adult population in Western world. Patients are nowadays treated by chemo-immunotherapy as a standard. One of the known factors influencing resistance to this therapy are mutations in the TP53 gene. A new therapeutic option for patients with TP53 mutations and relapsing patients is targeted biologic therapy, such as B-cell signaling inhibitors (ibrutinib and idelalisib) and Bcl2 signaling (venetoclax). Although new therapies achieve very good results in patients, they do not, as with chemo-immunotherapy, completely cure, and the residual tumor cell population presents the risk of relapse and resistance development. The aim of this project is to analyze the changes in the relapsing patients during both classical chemo-immunotherapy and targeted biologic therapy. Then find those changes associated with the development of resistance to therapy and the factors influencing the response and the duration of the remission.